Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis (NASH)

NCT04134091 is registered in ClinicalTrials.gov with Lipocine Inc. as lead sponsor.

NCT NCT04134091
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04134091 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis (NASH)
Lead sponsor
Lipocine Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 27, 2019
Completion date
June 24, 2021
Enrollment
56 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

nonalcoholic steatohepatitis (nash)